GroundRules
Tex. Health and Safety Code § 491.051: ESTABLISHMENT OF CONSORTIUM.
Where this section sits in the code
- HEALTH AND SAFETY CODE
- TITLE 6. FOOD, DRUGS, ALCOHOL, AND HAZARDOUS SUBSTANCES
- SUBTITLE C. SUBSTANCE ABUSE REGULATION AND CRIMES Chapter 491, consisting of Secs. 491.001 to 491.103, was added by Acts 2025, 89th Leg., R.S., Ch. 333 (S.B. 2308), Sec. 1. For another Chapter 491, consisting of Secs. 491.001 to 491.151, added by Acts 2025, 89th Leg., R.S., Ch. 285 (S.B. 984), Sec. 1, see Sec. 491.001 et seq., post. For another Chapter 491, consisting of Secs. 491.001 to 491.151, added by Acts 2025, 89th Leg., R.S., Ch. 352 (S.B. 670), Sec. 2, see Sec. 491.001 et seq., post.
- CHAPTER 491. IBOGAINE TREATMENT
- SUBCHAPTER B. DRUG DEVELOPMENT OF IBOGAINE TREATMENT
(a) A consortium may be established under this section and apply for commission selection under this subchapter to conduct drug development clinical trials with ibogaine and secure the United States Food and Drug Administration's approval of ibogaine as a medication for the treatment of:
(1) opioid use disorder;
(2) co-occurring substance use disorder; and
(3) any other neurological or mental health condition for which ibogaine demonstrates efficacy.
(b) A consortium established under this section must include one or more of each of the following entities:
(1) a drug developer;
(2) an institution of higher education; and
(3) a hospital.
Added by Acts 2025, 89th Leg., R.S., Ch. 333 (S.B. 2308), Sec. 1, eff. June 11, 2025.
Collected 2026-08-27T01:47:17Z. Source file · JSON